<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01500226</url>
  </required_header>
  <id_info>
    <org_study_id>TS-P04834</org_study_id>
    <nct_id>NCT01500226</nct_id>
  </id_info>
  <brief_title>Ph 3 Safety/Efficacy Study of Rolapitant for Prevention of CINV in Subjects Receiving Moderately Emetogenic Chemotherapy</brief_title>
  <official_title>Phase 3, Multicenter, Randomized, Double Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tesaro, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tesaro, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled
      study of rolapitant in subjects receiving MEC. Rolapitant or placebo will be administered
      prior to the initiation of chemotherapy on Day 1 with granisetron and dexamethasone. Subjects
      will record all events of emesis and the use of rescue medication for established nausea
      and/or vomiting, and will indicate the severity of nausea they experienced in each of the
      previous 24 hours in the Nausea and Vomiting (NV) Subject Diary prior to the MEC
      administration through Day 6 in Cycle 1. Health-related quality of life will be measured by
      the FLIE Questionnaire on Day 6 of Cycle 1. Safety and tolerability will be assessed by
      clinical review of adverse events (AEs), physical examination, electrocardiograms (ECGs), and
      safety laboratory values. All subjects are expected to complete Cycle 1 and will have the
      option of participating in up to five additional cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3, multicenter, randomized, parallel-group, double-blind, active-controlled
      study of rolapitant in subjects receiving MEC. Rolapitant or placebo will be administered
      orally 1-2 hours prior to the initiation of chemotherapy on Day 1. Granisetron (2 mg PO) and
      dexamethasone (20 mg PO) will be administered approximately 30 minutes before initiation of
      chemotherapy. Subjects will continue to receive granisetron (2 mg daily) on Days 2 and 3.
      Subjects will record all events of emesis and the use of rescue medication for established
      nausea and/or vomiting, and will indicate the severity of nausea they experienced in each of
      the previous 24 hours in the Nausea and Vomiting (NV) Subject Diary prior to the MEC
      administration through Day 6 in Cycle 1. Health-related quality of life will be measured by
      the FLIE Questionnaire on Day 6 of Cycle 1. Safety and tolerability will be assessed by
      clinical review of adverse events (AEs), physical and neurological examinations, vital signs,
      electrocardiograms (ECGs), and safety laboratory values including BUN and creatinine. All
      subjects are expected to complete Cycle 1 and will have the option of participating in up to
      five additional cycles. Blood samples may be collected and stored in this study and may be
      analyzed for future biomarker research related to safety and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No Emetic Episodes and No Rescue Medication</measure>
    <time_frame>&gt;24 to 120 hours post chemotherapy</time_frame>
    <description>The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt;24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving MEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (&gt;24 to 120 hours).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Phase Response</measure>
    <time_frame>0 to 24 hours</time_frame>
    <description>To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>0 to 120 hours</time_frame>
    <description>To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1369</enrollment>
  <condition>Chemotherapy-induced Nausea and Vomiting</condition>
  <arm_group>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Day 1: Placebo + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rolapitant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Rolapitant (200 mg PO) + Granisetron (2 mg PO)+ Dexamethasone (20 mg PO) Days 2-3: Granisetron (2 mg PO) will be administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rolapitant</intervention_name>
    <description>(4 X 50 mg capsule) 200 mg PO</description>
    <arm_group_label>Rolapitant</arm_group_label>
    <other_name>Varubi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granisetron</intervention_name>
    <description>2 mg PO</description>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <arm_group_label>Rolapitant</arm_group_label>
    <other_name>Kytril</other_name>
    <other_name>Granisol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg PO</description>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <arm_group_label>Rolapitant</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>(4 X 0 mg capsules) 0 mg PO</description>
    <arm_group_label>Placebo + Granisetron + Dexamethasone</arm_group_label>
    <other_name>Placebo to match Rolapitant</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older, of either gender, and of any race

          -  Naïve to moderately or highly emetogenic chemotherapy, and is to receive a first
             course of MEC including one or more of the following agents: cyclophosphamide IV
             (&lt;1500 mg/m2), doxorubicin, epirubicin, carboplatin, idarubicin, ifosfamide,
             irinotecan, daunorubicin, cytarabine IV (&gt;1 g/m2).

          -  Karnofsky performance score of ≥60

          -  Predicted life expectancy of ≥4 months

          -  Adequate bone marrow, kidney, and liver function

        Exclusion Criteria:

          -  Contraindication to the administration of prescribed MEC agent,granisetron, or
             dexamethasone

          -  Is pregnant or breast feeding

          -  Has taken the following agents within the last 48 hours 5-HT3
             antagonists,Phenothiazines,Benzamides,Domperidone,Cannabinoids,NK1 antagonist,
             Benzodiazepines

          -  Scheduled to receive any other chemotherapeutic agent with an emetogenicity level of 3
             or above (Hesketh Scale) from Day -2 through Day 6, except on Day 1

          -  Scheduled to receive any radiation therapy to the abdomen or pelvis from Day -5
             through Day 6

          -  Has received systemic corticosteroids or sedative antihistamines within 72 hours of
             Day 1 of the study except as premedication for chemotherapy (e.g., taxanes)

          -  Symptomatic primary or metastatic CNS disease.

          -  Has ongoing vomiting, retching, clinically significant nausea caused by any etiology,
             or has a history of anticipatory nausea and vomiting.

          -  Has vomited and/or has had dry heaves/retching within 24 hours prior to the start of
             MECon Day 1 in Cycle 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Vargo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tesaro, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TESARO Inc</name>
      <address>
        <city>Waltham</city>
        <state>Massachusetts</state>
        <zip>02451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2011</study_first_submitted>
  <study_first_submitted_qc>December 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2011</study_first_posted>
  <results_first_submitted>October 2, 2015</results_first_submitted>
  <results_first_submitted_qc>October 2, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 4, 2015</results_first_posted>
  <last_update_submitted>February 2, 2016</last_update_submitted>
  <last_update_submitted_qc>February 2, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rolapitant</keyword>
  <keyword>Nausea</keyword>
  <keyword>Vomiting</keyword>
  <keyword>CINV</keyword>
  <keyword>Chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Granisetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rolapitant + Granisetron + Dexamethasone</title>
          <description>Oral dose of rolapitant 180 mg (equivalent to 200mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy.
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy.</description>
        </group>
        <group group_id="P2">
          <title>Placebo + Granisetron + Dexamethasone</title>
          <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="684">Number of randomized patients</participants>
                <participants group_id="P2" count="685"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="185">Number of patients who completed 6 cycles</participants>
                <participants group_id="P2" count="191"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="499"/>
                <participants group_id="P2" count="494"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="38"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Chemo Completed or Change in Therapy</title>
              <participants_list>
                <participants group_id="P1" count="235"/>
                <participants group_id="P2" count="237"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="96"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reasons</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>684 subjects were randomized to Rolapitant and 685 were randomized to control;
670 of those randomized to Rolapitant received study drug in C1; 674 of those who were randomized to control received study drug in C1.
4 Rolapitant subject and 8 control subject were from GCP-non-compliant sites.
MITT = 666 Rolapitant and 666 control</population>
      <group_list>
        <group group_id="B1">
          <title>Rolapitant + Granisetron + Dexamethasone</title>
          <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
        </group>
        <group group_id="B2">
          <title>Placebo + Granisetron + Dexamethasone</title>
          <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="666"/>
            <count group_id="B2" value="666"/>
            <count group_id="B3" value="1332"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.7" spread="11.65"/>
                    <measurement group_id="B2" value="56.6" spread="12.01"/>
                    <measurement group_id="B3" value="56.7" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="531"/>
                    <measurement group_id="B2" value="536"/>
                    <measurement group_id="B3" value="1067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="130"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="584"/>
                    <measurement group_id="B2" value="593"/>
                    <measurement group_id="B3" value="1177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="508"/>
                    <measurement group_id="B2" value="512"/>
                    <measurement group_id="B3" value="1020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>No Emetic Episodes and No Rescue Medication</title>
        <description>The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt;24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving MEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (&gt;24 to 120 hours).</description>
        <time_frame>&gt;24 to 120 hours post chemotherapy</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Rolapitant + Granisetron + Dexamethasone</title>
            <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Granisetron + Dexamethasone</title>
            <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>No Emetic Episodes and No Rescue Medication</title>
          <description>The primary objective of this study is to determine whether administration of rolapitant with granisetron and dexamethasone improves CINV in the delayed phase (&gt;24 to 120 hours) of CINV compared with administration of placebo with granisetron and dexamethasone in subjects receiving MEC. The primary outcome will be based on complete response (defined as no emesis and no rescue medication) in the delayed phase (&gt;24 to 120 hours).</description>
          <population>MITT</population>
          <units>percentage of particpants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="666"/>
                <count group_id="O2" value="666"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" lower_limit="67.7" upper_limit="74.7"/>
                    <measurement group_id="O2" value="61.6" lower_limit="57.7" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for multiplicity, analyses were performed hierarchically. For the CR delayed the threshold for statistical significance was 0.05; no further adjustment for multiplicity were required for the primary endpoint.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran Mantel Haenszel (CMH) test was stratified by sex. Missing data were imputed as treatment failures.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Phase Response</title>
        <description>To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.</description>
        <time_frame>0 to 24 hours</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Rolapitant + Granisetron + Dexamethasone</title>
            <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Granisetron + Dexamethasone</title>
            <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Phase Response</title>
          <description>To determine the effect of rolapitant on complete response rates in the acute (0 to 24 hours) phase of CINV.</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="666"/>
                <count group_id="O2" value="666"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" lower_limit="80.4" upper_limit="86.2"/>
                    <measurement group_id="O2" value="80.3" lower_limit="77.1" upper_limit="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.143</p_value>
            <p_value_desc>To control for multiplicity, analyses were performed hierarchically. CR-acute was tested only if the result for the primary endpoint, CR delayed, was statistically significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran Mantel Haenszel (CMH) test was stratified by sex. Missing data were imputed as treatment failures.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate</title>
        <description>To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.</description>
        <time_frame>0 to 120 hours</time_frame>
        <population>MITT</population>
        <group_list>
          <group group_id="O1">
            <title>Rolapitant + Granisetron + Dexamethasone</title>
            <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
          </group>
          <group group_id="O2">
            <title>Placebo + Granisetron + Dexamethasone</title>
            <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate</title>
          <description>To determine the effect of rolapitant on complete response rate in the overall (0 to 120 hours) phase of CINV.</description>
          <population>MITT</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="666"/>
                <count group_id="O2" value="666"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" lower_limit="64.9" upper_limit="72.1"/>
                    <measurement group_id="O2" value="57.8" lower_limit="54.0" upper_limit="61.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>To control for multiplicity, analyses were performed hierarchically. CR overall was tested only if both CR delayed and CR acute were statistically significant.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran Mantel Haenszel (CMH) test was stratified by sex. Missing data were imputed as treatment failures.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.3</ci_lower_limit>
            <ci_upper_limit>2.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 6 cycles (median number of cycles=4; median duration of each cycle = 21 days) of treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rolapitant + Granisetron + Dexamethasone</title>
          <description>Oral dose of rolapitant 180 mg (equivalent to 200 mg rolapitant hydrochloride monohydrate) 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy
684 subjects were randomized to Rolapitant
670 of those randomized to Rolapitant received rolapitant in C1
Safety = 670 Rolapitant</description>
        </group>
        <group group_id="E2">
          <title>Placebo + Granisetron + Dexamethasone</title>
          <description>Matching placebo 1–2 h before administration of chemotherapy
Granisetron (2 mg orally) about 30 min before chemotherapy. Subsequently, granisetron 2mg was administered orally to all patients once daily on days 2–3
Dexamethasone (20 mg orally) about 30 min before chemotherapy
685 subjects were randomized to control
674 of those who were randomized to control received control in C1
Safety = 674 control</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="103" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Cardio-Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Jejunal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Catheter Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Device Related Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Fungaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Mucosal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Oral Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pelvic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Peridiverticular Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>C-Reactive Protein Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Metastases to Peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Neoplasm Progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Partial Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Posterior Reversible Encephalopathy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (15.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="540" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="542" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="96" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="114" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="179" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="183" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Mucosal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="87" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="71" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="674"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="670"/>
                <counts group_id="E2" subjects_affected="172" subjects_at_risk="674"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin Huber, M.D., Senior Vice President and Chief Medical Officer</name_or_title>
      <organization>Tesaro</organization>
      <phone>781-257-2536</phone>
      <email>mhuber@tesarobio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

